PhRMA DTC Guideline Compliance Could Avert Plaintiff, DoJ Backlash – Troy
Executive Summary
Responding to warning and untitled letters from FDA's Division of Drug Marketing, Advertising & Communications could help to shield firms in the event of product liability suits, according to former FDA Chief Counsel Daniel Troy
You may also be interested in...
Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says
Uncontrolled studies published in peer-reviewed journals should be acceptable as promotional information if disseminated with an FDA disclaimer, the Washington Legal Foundation said during FDA's public hearing on direct-to-consumer advertising Nov. 1-2
Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says
Uncontrolled studies published in peer-reviewed journals should be acceptable as promotional information if disseminated with an FDA disclaimer, the Washington Legal Foundation said during FDA's public hearing on direct-to-consumer advertising Nov. 1-2
PhRMA DTC Principles Compliance To Get Independent Panel Review In 2007
PhRMA is giving itself one year to monitor member companies' implementation of its new direct-to-consumer "guiding principles" before an independent panel will begin analyzing compliance and progress